FORT LAUDERDALE, Fla., March 10, 2009 (GLOBE NEWSWIRE) -- Cross Atlantic Commodities, Inc. (Pink Sheets:CXAC), is proud to announce it has signed a Letter of Intent (LOI) to acquire T-3 Media Inc.
Jorge Bravo, President and CEO of CXAC, stated, "We are extremely thrilled to be announcing today's news. Management has worked tirelessly to bring value back to CXAC shareholders and today's news is without a doubt the biggest news we have had to report in a very long time. T-3 Media has two patents in which it generated an unprecedented $1 million in revenue in 2008 from the marketing and distribution of OMG!(tm) products. Stephan Todd Smith is the mastermind behind T-3 and CXAC is honored to have him as a new addition to our team."
"T-3 is a perfect fit; CXAC seeks to generate multiple streams of income from a variety of products that appeal to the masses. Both products offered through T-3 are unquestionably the perfect fit for the new CXAC and shall do very well for our bottom line," stated Bravo.
Stephan Todd Smith, CEO of T-3 Media, Inc., stated, "T-3 Media, Inc. (T-3) will become a wholly owned subsidiary of CXAC with the intention of marketing our patented lifestyle enhancement products for women. T-3 enters this arrangement with CXAC with high expectations that the quality products produced by T-3, coupled with the sales and marketing platform of CXAC, will result in outstanding earnings and investor return."
With T-3 as a wholly owned subsidiary of CXAC Jorge Bravo will remain CEO of CXAC and Stephan Todd Smith will become President of T-3 Media, Inc. and shall become a Director of CXAC.
"T-3 will maintain its relationships with key pharmaceutical personnel allowing for advisory panel input from industry experts with regards to product information and further research and development. The advisory panel consists of pharmaceutical experts who have launched products producing billions of dollars in revenue including Xanax, Depo Provera, Motrin, Viagra, and Lipitor just to name a few. T-3 enters this arrangement with full faith and confidence that this is the most advantageous strategic partnership with regards to product promotion and launch, effective corporate management and shareholder value," concluded Smith.
"Today's news does not impact our decision of a reverse split; I want to reiterate that CXAC will not conduct a reverse split of its stock during the second quarter, and our board of directors will meet in the near future to deliberate on announcing the extension of this policy to include the rest of 2009. We are talking the talk and have begun to walk the walk. Today is a new day for CXAC," Bravo said.
About T-3 Media, Inc.: Founded in 2008, T-3 Media Inc. is a Nevada corporation headquartered in Atlanta, Georgia that markets and distributes OMG!(tm) products; OMG!(tm) feminine gel and Lip Plump. T-3 Media has two patents for its OMG!(tm) feminine gel that was developed by a gynecologist, FDA cleared, and is clinically proven to be VERY effective! T-3 Media Inc. OMG!(tm) products can be viewed at http://www.omggel.com/products.htm.Posts: 28 | Registered: Jan 2008
| IP: Logged |
posted
Weston, FL, Mar 12, 2009 (WORLD STOCK WIRE via COMTEX) -- CXAC | Quote | Chart | News | PowerRating -- Cross Atlantic Commodities, Inc. (PINK SHEETS: CXAC), a distributor of specialty "quality of life" enhancement products, today unveils its 2009 business plan.
CXAC is presently working on closing the formal paperwork for the T-3 Media Merger. As we previously announced, this is a binding letter of intent, as such our attorney's are aggressively tying up all loose ends in the paperwork for finalization on schedule, as per our announcement, for March 17th, 2009.
Our web design firm is working on integrating the companies corporate sites, to include the patented OMG Gel and Lip Plumper on http://www.crossac.com. Our CPA firm Kim Marks CPA is consolidating the balance sheets to prepare for incorporating the T-3 Medias revenues into our balance sheet. Once these steps are completed, CXAC will begin to market its new product line through its distribution of Direct Response, adding to the 1 million dollars revenues for T-3 Media in 2008.
We are presently considering a spin-off of our other subsidiaries, Black White Coffee, Arie Luyendyk Waterless Wash & Wax, and Fruit 2 go. This decision was made in the interests of concentrating on what generates ideal revenues.
CEO Jorge Bravo stated, "We announced the launch of Rejuv by Caci and sold 390 units in the first week of market testing, We then added a more attractive offer, which launches the second phase of market testing tomorrow. This second phase, will serve as an evaluation, to determine either our third phase program adjustments, or in the event we reach our return objectives, a model to proceed directly to mass media release. Once our return rate is achieved, we then go with the full program of $100k a week in media buying. We are anticipating revenues on the $100k a week program, to achieve $225,000.00 in potential revenues a week."
Posts: 28 | Registered: Jan 2008
| IP: Logged |
Cross Atlantic Commodities, Inc. Completes and Finalizes T-3 Media Inc Merger 8:30a ET March 16, 2009 (GlobeNewswire) Cross Atlantic Commodities, Inc. (Pink Sheets:CXAC), a distributor of specialty "quality of life" enhancement products, is proud to announce that the merger with T-3 Media is finalized. The merger was signed by both parties over the weekend by Todd Smith, President of T-3 Media, and Jorge Bravo, C.E.O. of CXAC.
Under the term of the merger, T-3 Media is now a wholly owned subsidiary of CXAC. T-3 will receive 10% of the outstanding shares of CXAC in restricted stock; these shares will be restricted for two years, with an earn-out when successful milestones are reached.
Todd Smith will head T-3 as president; and Jorge Bravo remains C.E.O. of Cross Atlantic Commodities. Kim Marks will be the CPA; he will prepare all financial information on both companies. Once financial statements and disclosures are completed, Jorge Bravo will upload the documents to pinksheets.com.
Jorge Bravo states, "We are very excited about bringing in T-3 Media's product line under CACI's umbrella. OMG! Gel will be marketed as a stand-alone product, and follow the same business model as Rejuv by Caci. Our goal in a very short period is to get OMG! Gel sold through Direct Response and to get it to $100,000.00 per week in media buying.
"With the Emerge Lip Plumper, we plan on cross marketing this product with Rejuv by Caci. This product is a perfect fit with Rejuv by Caci and we will be adding it to our line in the near future."
More details about the products, plans, and company developments are to follow in the media this week.
About Cross Atlantic Commodities, Inc.
Cross Atlantic Commodities, Inc. is a publicly traded company under the symbol CXAC. For more information about our products and company, please visit www.crossac.com
Cross Atlantic Commodities, Inc. develops, acquires, markets and distributes specialty "quality of life" enhancement products and general merchandise to the public via direct response marketing, direct marketing and eventually mass retail/wholesale distributors. Products the company is currently focusing on include:
Rejuv by Caci(r) is our immediate results anti-aging cream. OMG! Gel Emerge Lip Plumper
Please review our PowerPoint presentations for a complete description of our new products.
Cross Atlantic Commodities Inc, Letter to Shareholders
Weston, FL - (WORLD STOCK WIRE) - March 17, 2009 -- Cross Atlantic Commodities, Inc. (PINK SHEETS: CXAC - News), a distributor of specialty “quality of life” enhancement products, announces to do numerous questions we are receiving on and about T-3 Media Inc, Cross Atlantic is proud to announce a letter to its shareholders from Todd Smith.
Mr. Todd Smith president of T-3 Media Inc Released a Letter to Cross Atlantic Shareholders explaining the company’s origins and advances patents and trademarks.
Dear Shareholders, I am the President of T3 Media Holdings, Inc. a company created and developed to enhance the lives of women and happy healthy couples... Our Gynecologist and Surgeon, Dr. Ronald J. Thompson, developed our patented products. Infertility, Gynecology, Urology and Women’s Health have been the focus of many of our development initiatives. One of the first technologies we developed, and currently the most successful in terms of revenue, is a topical OTC L-arginine/menthol product to increase clitoral blood flow and sexual responsiveness in women.
Working with our intellectual property partners 40 J’s, LLC, we have two granted patents, US Patent No’s 6,322,493 and 6,702,733 (many more pending), that cover the use of menthol and l-arginine topically to increase clitoral blood flow. The menthol acts as an initial vasodilator and a vehicle to aid in the absorption of the l-arginine, the substrate for the NOS pathway. The l-arginine is converted locally to nitric oxide, which has a vasodilatory effect on the clitoral tissue, producing a clitoral erection (necessary for full sensation, arousal and orgasm by a woman during intercourse).
Through the advancement of this technology, we studied additional pharmacologic ingredients to make the product more effective. We believe that adding a 5-PDE inhibitor, sildenafil that is the active drug in Viagra in particular, to the combination would have an additive, synergistic effect (US Pat App 10/803148). Menthol would cause an initial vasodilatation and aid in the delivery of both the l-arginine and sildenafil to the clitoral tissues. The conversion of l-arginine to nitric oxide would begin immediately in the clitoral tissues, providing initial vasodilatation. Sildenafil, through its normal pharmacologic activity, would inhibit NO breakdown and provide a lasting, sustained clitoral erection throughout intercourse. This clitoral erection would signal a woman’s sexual arousal and allow her to achieve orgasm(s) during intercourse, two of the indications for Female Sexual Dysfunction.
We believe a topical product will be more effective and safer than any oral treatment for women;
1) The time from application to pharmacologic effect of the topical sildenafil/L-arginine/menthol product would be almost immediate (minutes), compared to an oral product that might take upwards of an hour to be effective. From a customer usage marketing perspective women are not going to wait for the oral product to begin working before they lose the “mood.”
2) Episodic use of a product, when having sexual activity, may be viewed favorably by the FDA, when compared to a daily use oral product.
3) The total amount of sildenafil needed in a topical dose would much lower than an equivalent oral dose, so any side effects from the systemic absorption (to the degree that it is systemic) would be minimal, if any. In addition, from a marketing perspective, women are not going to tolerate negative side effects as a man would.
We have performed regulatory due diligence in an effort to determine the timeline and studies necessary to support a NDA for the FSD indication. With the help of Bill Sietsema and Melanie Bruno of Kendle, we believe we could have an FDA approvable NDA filing for the treatment for Female Sexual Dysfunction within 24 months.
To date, only one drug candidate has ever filed for approval from the FDA for product launch and it was denied due to safety issues. The negative safety issues related to Lilly’s drug candidate, Intrinsa, were associated with the manipulation of testosterone in women. By creating our topical version, we have determined through preliminary studies, begun in 2005 with Bayer that our drug candidate will not create any safety issues for patients and will help millions of women achieve their most rewarding and fulfilling sexual health possible.
Our level of development is years beyond that of our competitors and we are extremely optimistic about the positive results for women and the impact on shareholder value. Within our Research and Development Division, been reviewing the possibility of a prescription strength indication for Female Sexual Dysfunction (FSD). Combining the active drugs found in Erectile Dysfunction products for men with our patented chemical compound, we have already undergone studies for this indication with major pharmaceutical companies including Bayer. Phase I and Phase II trials, with proper funding, will be completed within 24 months and a product for the multi-billion dollar FSD market would be ready for launch within 36 months. An estimated $2 million has already been spent on studies to date.
The market for Female Sexual Dysfunction is considered three times that of the male counterpart market, which is worth billions of dollars a year in revenue. The FDA just recently wrote the guidelines for treatment of FSD (female sexual dysfunction) and we are positioned to become the first Doctor prescribed product to meet the needs of women.
According to Drs. William Sietsema, Melanie Bruno, and Martha Feller in their article titled “From Taboo to Treatment” in the Good Clinical Practice Journal, “Sexual health has been a taboo subject in many quarters – most people preferring to keep their sexual problems to themselves for fear of incurring disapproval or worse, ridicule. However, the media hype around Viagra has encouraged sexual dysfunction and a global revenue of US$1.87 billion from Viagra sales in 2003 alone has prompted pharma to investigate the area more thoroughly. The spotlight has turned to female sexual dysfunction (FSD) as a much-cited report found that 43% of women suffer from sexual problems, compared with only 31% of men.”
Becoming the first to market an FSD product to women would result in billions of dollars in sales. Clearly, this is a priority addition to our already successful over the counter product suite.
Kind Regards,
Stephan Todd Smith CEO T3 Media Holdings, Inc.
Posts: 28 | Registered: Jan 2008
| IP: Logged |
Cross Atlantic Commodities, Inc. Releases New Commercial Schedule for Re Juv by Caci
FORT LAUDERDALE, Fla., Mar 20, 2009 (GlobeNewswire via COMTEX) -- Cross Atlantic Commodities, Inc. (Pink Sheets:CXAC), a distributor of specialty "quality of life" enhancement products, releases new commercial schedule.
"We are proud to announce that we will be running the second round of testing starting Friday, March 27th through Thursday, April 2nd, 2009, and are very excited about our new 14 day free offer," states Jorge Bravo, President & CEO of CXAC. We are running on the following stations:
CW 100+ (10 million subscribers) Friday-Thursday 9 a.m. - 12 a.m., 10 spots, Discovery Health (45 million subscribers) Friday-Thursday 3 a.m. - 6 a.m., 5 spots, FiTv (38 million subscribers) Friday-Thursday 6 a.m. - 9 a.m., 10 spots, and Friday-Thursday 11 a.m. - 2 a.m., 10 spots, which is a total of 35 spots.
We are expecting a viewing of greater than 92 million and to sell over 1000 units. As previously announced, the company just completed its merger with T-3 Media and will be launching its new products in the near future. We invite all past, present and future shareholders to order our Re Juv by Caci by calling 1-888-661-2309 starting Monday, March 23rd.
Posts: 28 | Registered: Jan 2008
| IP: Logged |
posted
Cross Atlantic Commodities Inc, Begins Scripting Commercial for OMG! Gel
Weston, FL, Mar 23, 2009 (WORLD STOCK WIRE via COMTEX) -- Cross Atlantic Commodities, Inc. (PINK SHEETS: CXAC - News), a distributor of specialty "quality of life" enhancement products, begins scripting commercial for OMG! Gel, in preparation for commercial launch in 45 days. CXAC & T3 would also like to announce the upcoming Television launch of its OMG! Brands for its National Cable Launch. "We are now beginning to script our commercial for OMG! Gel, and are following the same model as Re Juv by Caci, and hoping to have the first test within 45 days to get to the $100,000.00 a week in Media Buying, states Jorge Bravo President & CEO of Cross Atlantic Commodities Inc". T3 is sure the reception of our products will be even more enthusiastic than it was overseas where our patented formulas sold over $250 million of product through "BHIP" a licensor of the products, states Todd Smith, President of T3. OMG! Gel's patented formula has satisfied millions of customers all over the world. T3 believes with the marketing expertise of CXAC driving the products to market we should exceed the overseas numbers showing America is still the leader of the free thinking world.
Posts: 28 | Registered: Jan 2008
| IP: Logged |
1. Current capital structure is not going to change now or in the immediate future. Meaning no R/S or A/S increase.
2. End of April or early May we should have a celebrity endorsement.
3. Press expansion is being addressed, current releases were done cause national press is costly, they were trying to inform the shareholders as to the plans and current happenings.
4. MLM Legal issues do not have any effect on CXAC or T-3.
5. Profit margin for OMG!Gel Cost Retail Sample Pack .30/ea $10-15 sold in 3 packs Vial $2.50 $19.95
6. Questions from IHUB Pinksmeanslosing.... 4) What are the Scenarios's that you guys have in place when the face cream fails. they do not believe it will fail. but they have other products that can be moving in case it does.
5) Can we have an update ( counter ) of the number of tubes purchased, updated per day? due to having this in multiple fulfillment houses the daily numbers would be difficult but they will try and come up with a better way of releasing this information more frequently.
7. financials for T-3 for 2007 and 2008 will be released tomorrow. (wants people to remember these numbers for T-3 are wholesale not retails sales... and should be multiplied by 10)
8. Full disclosure to pinksheets is on the horizon. Jorge was in contact with them today.
This is about all that I was able to write down. If there was anything I missed please feel free to add or update if I made any mistakes too.
Posts: 28 | Registered: Jan 2008
| IP: Logged |
posted
Cross Atlantic Commodities, Inc. Signs International Internet Marketing Agreement With Big Ray Gun
Last update: 8:04 a.m. EDT May 6, 2009 MIAMI, May 6, 2009 (GlobeNewswire via COMTEX) -- Cross Atlantic Commodities, Inc. (Pink Sheets:CXAC), a distributor of specialty "quality of life" enhancement products, signs marketing agreement with Big Ray Gun for e-mail and online campaign. In announcing this agreement, CXAC CEO Jorge Bravo emphasized the tremendous marketing reach of the program. Big Ray Gun ( www.bigraygun.com) has over 70,000 affiliates. Tapping into this program will compliment our TV and direct mail advertising programs. "This opportunity is sure to put Re Juv by Caci, our lead product, in front of millions of consumers," said Bravo. In addition, an agreement to fund $100,000 per week of TV media is now in place. The funding is based upon specific sales results from a test airing set to "kick off" on May 11, 2009. To assure a successful launch, all three marketing programs will start simultaneously. About Big Ray Gun: Big Ray Gun is a creative agency whose well-honed expertise offers unique value and voltage to a variety of online and offline projects. Working with diverse clients on these campaigns is the fluid foundation that Big Ray Gun thrives on: by bringing artisan-level execution to each and every project, be it an online marketing campaign, website, direct mail solution, or a viral/interactive experience -- a unique solution is derived. BRG was not made from a cookie cutter -- nor does BRG sell cookie-cut solutions. It should come as no surprise then that Big Ray Gun contains a host of talents which, when combined in whole or in part, create a myriad of opportunities to solve a creative problem -- creatively.
Posts: 28 | Registered: Jan 2008
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
